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Mechanistic ⁄ mammalian target protein of rapamycin (mTOR) is
an evolutionarily conserved kinase that plays a critical role in
sensing and responding to environmental determinants such as
nutrient availability, energy sufficiency, stress, and growth factor
concentration. mTOR participates in two complexes, designated
mTOR complex 1 (mTORC1) and 2 (mTORC2), both of which phos-
phorylate multiple substrates. Recent studies have revealed that
the fine-tuning activity of mTOR complexes contributes to both
maintenance of hematopoietic stem cells (HSCs) and suppression
of leukemogenesis. Dysregulation of mTORC1 activity results in
impaired HSC homeostasis. Abnormalities of mTOR signaling are
observed in many patients with leukemia and genetic studies
clearly show that the leukemogenesis associated with Pten defi-
ciency involves both mTORC1 and mTORC2. Although the several
mTOR inhibitors have been developed for cancer therapy, effec-
tiveness of the inhibitors for eradication of leukemia stem cells
(LSCs) is unknown. Advances in understanding of how mTOR sig-
naling is involved in mechanisms of normal HSC and LSC homeo-
stasis may lead to novel therapeutic approaches that can
successfully eradicate leukemia. (Cancer Sci 2013; 104: 977–982)
Improved cell purification and transplantation techniqueshave contributed to the identification of cell populations
known as leukemia-initiating cells, leading to the idea that
leukemias are organized as hierarchies of leukemia cells that
are sustained by rare leukemia stem cells (LSCs).(1) Previous
studies have suggested that shared mechanisms regulate stem
cell properties (stemness) in both hematopoietic stem cells
(HSCs) and LSCs,(2) leading to the hypothesis that LSCs may
originate from HSCs. Several lines of evidence indicate that
chronic myelogenous leukemia (CML) originates from HSCs
that have sustained the chromosomal translocation.(3) On the
other hand, recent findings have suggested that acute myeloid
leukemia (AML) can originate from myeloid progenitors and
acquire stemness properties during leukemogenesis.(4–7)
Despite the differing origins of LSCs among different leuke-
mias, there appears to be a common regulatory mechanism
governing “stemness” and thus the behavior of HSCs and
LSCs.
A current topic in the stem cell research field is the regula-
tion of HSC homeostasis by the fine-tuning of mechanistic ⁄
mammalian target protein of rapamycin (mTOR) signaling.
mTOR is an evolutionarily conserved kinase that plays a criti-
cal role in sensing and responding to environmental determi-
nants such as nutrient availability, energy sufficiency, stress,
and growth factor concentration.(8,9) Because HSCs reside in a
hypoxic bone marrow environment and use glycolysis, rather
than mitochondrial oxidative phosphorylation, to meet their
energy demands,(10) molecules used in regulation of cellular
metabolism such as mTOR are vital for HSC homeostasis. In
addition, recent studies have demonstrated that the activation
of mTOR complexes also regulates the leukemogenesis.
Understanding the roles of mTOR signaling in stemness of leu-
kemias is important because mTOR inhibitors have been
developed for cancer therapy. In this article, we focus on the
molecular aspects of how mTOR signaling may be involved in
the homeostasis of normal HSCs and LSCs.
mTOR Signaling Pathways
Regulation ofmTOR complex 1 activity. mTOR is a serine ⁄ threo-
nine protein kinase that belongs to the phosphoinositide-3-
kinase (PI3K)-related kinase family. mTOR participates in two
complexes, designated mTOR complex 1 (mTORC1) and 2
(mTORC2),(8,9) both of which phosphorylate multiple sub-
strates. mTORC1 consists of mTOR, regulatory-associated pro-
tein of mTOR (Raptor), mammalian lethal withsec-13 protein
8 (mLST8 ⁄GbL), DEP domain-containing mTOR-interacting
protein (DEPTOR), 40 kDa Pro-rich AKT substrate (PRAS40;
also known as AKT1S1), and the Tel2-interacting protein
(Tti1) ⁄Tel2 complex (Fig. 1).
mTORC1 activation is induced by growth factors, cytokines
or insulin. Activation of PI3K via receptor tyrosine kinases
(RTKs) in response to these stimuli leads to phosphorylation
of phosphatidylinositol-4,5-bisphosphate (PIP2) to form PIP3.
This increase in PIP3 recruits AKT (also known as protein
kinase B [PKB]) to the membrane, where it is phosphorylated
by phosphoinositide-dependent kinase 1 (PDK1). One of the
substrates of AKT is tuberous sclerosis 2 (TSC2; also known
as tuberin). A heterodimer of TSC2 and TSC1 (also known as
hamartin) exhibits GTPase-activating protein (GAP) activity
towards Ras homolog enriched in brain (Rheb), converting it
to the inactive GDP bound form. Because GTP-loaded Rheb is
vital for the activation of mTOR kinase activity,(11,12) and
AKT-mediated phosphorylation of TSC2 blocks TSC’s inhibi-
tion of Rheb activity, AKT effectively activates mTORC1
through the TSC complex. AKT also activates mTORC1 in a
manner independent of the TSC1 ⁄TSC2-Rheb pathway,
because AKT-induced phosphorylation of PRAS40 results in
its dissociation from mTORC1.(13–16) In addition to the PI3K-
AKT pathway, mTORC1 can be activated by extracellular-sig-
nal-regulated kinase 1 ⁄2 (ERK1 ⁄2)-ribosomal S6 kinase
(RSK1) pathway, mediated with TSC1 ⁄TSC2 complex.(17)
WNT can also stimulate mTORC1 because WNT inactivates
glycogen synthase kinase 3b (GSK3b), which phosphorylates
TSC2.(18)
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As well as by the above growth factor signaling pathways,
mTORC1 activity is influenced by changes in intracellular
energy and oxygen conditions. For example, the essential energy
sensor AMP-activated protein kinase (AMPK) can regulate
mTORC1 activity. Under conditions of glucose starvation, AMP
levels rise and AMPK activity increases in a manner dependent
on the tumor suppressor liver kinase B1, resulting in AMPK-
mediated phosphorylation of TSC2 and mTORC1 inactiva-
tion.(19) AMPK can also directly phosphorylate Raptor, again
inhibiting mTORC1.(20) Under conditions of hypoxia, hypoxia-
inducible factor 1a (HIF1a) is upregulated and induces DNA
damage response 1 (REDD1), which enhances the activity of the
TSC complex and inhibits mTORC1.(21,22)
Amino acids, particularly leucine and glutamine, are impor-
tant regulators of mTORC1 activation. A member of the mam-
malian Rag small GTPase family, such as RagA or RagB,
interacts with RagC or RagD to form a heterodimeric complex
that is constitutively anchored on the surface of the lyso-
some.(23,24) Upon amino acid deprivation, RagA or RagB
becomes loaded with GDP and unable to recruit mTORC1 to the
lysosome surface which is a location for mTORC1 activation.(25)
Targets of mTORC1. mTORC1 controls multiple cellular pro-
cesses, including protein synthesis, glucose metabolism, fatty
acid and sterol synthesis, mitochondrial biogenesis, and auto-
phagy.
Protein synthesis. The assembly of the eukaryotic translation
initiation factor 4F (eIF4F) complex on the 5′ cap structure of
mRNA is required for initiation of translation.(8) This interac-
tion is controlled by 4EBP1 (inhibitory 4E-binding protein 1;
also known as eIF4EBP1). When hypophosphorylated, 4EBP1
binds tightly to eIF4E and prevents it from interacting with
eIF4G. Phosphorylation of 4EBP1 by mTORC1 leads to its
dissociation from eIF4E, allowing the recruitment of eIF4G to
the 5′ cap and translation initiation. Another set of direct
targets of mTORC1 in this context are the p70 ribosomal pro-
tein S6 kinases (p70S6Ks). S6Ks phosphorylate many proteins,
including ribosomal protein S6 (RPS6), eukaryotic translation
elongation factor 2 kinase (eEF2K), cap-binding protein 80
(CBP80), S6K1 Aly ⁄REF-like substrate (SKAR), eukaryotic
translation initiation factor 4B (eIF4B), and programmed cell
death 4 (PDCD4). mTORC1-mediated phosphorylation of these
molecules leads to stimulation of mRNA biogenesis as well as
translation initiation and polypeptide elongation. mTORC1
controls the translation of a set of genes that possess a 5′
terminal oligopyrimidine tract (5′ TOP). Many of these genes
encode ribosomal proteins or translation elongation factors.
Lipogenesis. mTORC1 is required for AKT-dependent lipo-
genesis, and a key set of targets involved in this process are
sterol regulatory element-binding proteins (SREBPs).(26) As
master transcriptional regulators of lipid metabolism, SREBPs
control the expression of genes encoding enzymes, including
acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN),
and stearoyl-CoA desaturase 1 (SCD-1), required for fatty acid
and cholesterol biosynthesis.(27) mTORC1 regulates SREBP by
controlling the nuclear entry of lipin 1, a phosphatidic acid
phosphatase.(28) Dephosphorylated, nuclear, catalytically active
lipin1 promotes nuclear remodeling and mediates the effects of
mTORC1 on SREBP target genes. In addition, mTORC1
induces the expression of peroxisome proliferator-activated
receptor-c (PPAR-c), which is mediated by CCAAT ⁄ enhancer
binding protein-b (C ⁄EBP-b), C ⁄EBP-d and C ⁄EBP-a. Induc-
tion of PPAR-c results in the upregulation of the uptake,
synthesis and esterification of fatty acids and their storage in
adipose cells.
Energy metabolism. mTORC1 is crucial for several pathways
of intracellular energy metabolism. mTORC1 activates the gly-
colytic flow by HIF1a activation, as well as the mitochondrial
biogenesis mediated by PPAR-c coactivator 1a (PGC1a) and
the transcription factor Ying-Yang 1 (YY1).(29,30) Activation of
both pathways contributes to elevation of ATP levels. In con-
trast, inhibition of mTORC1 activates autophagy, a system that
degrades proteins to generate energy for survival under condi-
tions of stress or starvation.(31) An interaction between Raptor
and the autophagy-related gene 1(Atg1) ⁄UNC-51-like kinase 1
(ULK1) kinase mediates the incorporation of mTORC1 into the
ULK1-Atg13-FAK family-interacting protein of 200 kDa
(FIP200) complex, which is required for autophagy. mTOR can
phosphorylate Atg1 ⁄ULK1 and Atg13, suggesting that auto-
phagy is directly regulated by mTORC1.(32)
Feedback loop by mTORC1 inhibition. To identify new pro-
teins whose phosphorylation is regulated by mTOR, large-
scaled phosphoproteomics analyses have been performed.(33,34)
Such studies have provided valuable information about the
existing and novel mTOR target molecules, including those
involved in negative feedback loops. mTORC1 activation
suppresses the PI3K-AKT pathway in a negative feedback
loop. A known mechanism underlying this loop is the destabi-
lization of insulin receptor substrate-1 (IRS-1) by phosphory-
lated S6K1. However, growth factor receptor-bound protein 10
(Grb10) was identified as a new target of mTORC1 in this
context through these studies.(33,34) It had been previously
reported that Grb10 negatively regulates growth factor signal-
ing by binding to the insulin and insulin-like growth factor 1
(IGF-1) receptors. The phosphoproteomics studies revealed
that mTORC1-mediated phosphorylation stabilizes Grb10,
leading to feedback inhibition of the PI3K. Grb10 also contrib-
utes to the suppression of tyrosine phosphorylation of IRS1
and IRS2, and to p85 PI3K recruitment by IRSs. In addition,















































Fig. 1. mTOR signaling pathways. mTOR associates with the indi-
cated molecules to form the mTORC1 and mTORC2 complexes.
mTORC1 activity is regulated by a variety of determinants, including
growth factors, cytokines, amino acids, hypoxia and energy sources.
Numerous signaling molecules, including PI3K, AKT, RAS, TSC1 ⁄ 2,
Rheb, AMPK, HIF1a, GSK3b, and Rag, are involved in the regulation of
mTORC1 activity, which controls protein synthesis, lipid synthesis, gly-
colysis, energy metabolism and autophagy. Although much less is
known about mTORC2, PI3K signaling reportedly stimulates the activ-
ity of this complex, which influences cell survival, metabolism, and
cytoskeletal organization.
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Grb10 may be a tumor suppressor that is regulated by
mTORC1. Thus, identification of feedback signals can open up
new areas of investigation in mTOR biology.
mTOR complex 2. The mTORC2 consists of mTOR, Rapamy-
cin-insensitive companion of mTOR (Rictor), mLST8, SAPK-
interacting protein (SIN1), DEPTOR, Tti1 ⁄Tel2 and protein
observed with Rictor (Protor) (Fig. 1). mTORC2 has not been
as well studied as mTORC1, and although insulin signaling is
known to stimulate mTORC2, the mechanism is undefined. It
was recently demonstrated that insulin-induced PI3K signaling
stimulates an interaction between mTORC2 and ribosomes that
promotes mTORC2 activation.(35) Activated mTORC2 phos-
phorylates the AGC kinases, which are named for protein kin-
ases A, G and C. Known substrates of mTORC2 are AKT
(S473, T450), serum ⁄glucocorticoide-regulated kinase 1
(SGK1), and PKCa. At the cellular level, mTORC2 regulates
cell shape by phosphorylating and activating PKC-a, which
influences the actin cytoskeleton.(36,37) It has been reported that
mTORC2 inactivation leads to a failure in the phosphorylation
of AKT(S473), which in turn leads to the activation of the
Forkhead box class O transcription factor (FoxO) 1 ⁄3a tran-
scription factors, while other AKT targets, TSC2 and GSK3,
and the TORC1 effectors, S6K and 4E-BP1, are not
affected.(38,39) Further studies regarding upstream and down-
stream signals are needed to understand physiological roles of
mTORC2.
mTOR Signaling in HSCs
Downregulation of mTORC1 is essential for HSC homeostasis.
Within their bone marrow (BM) niche, HSCs adopt a quiescent
state and remain in the non-dividing G0 phase of the cell cycle
until the generation of additional HSCs ⁄progenitors is required.
This quiescence of HSCs is also critical for the maintenance
of their self-renewal capacity, which is essential for the main-
tenance of appropriate HSC numbers.(40) AKT is highly phos-
phorylated and activated in most hematopoietic progenitor
cells but suppressed in freshly isolated HSCs, indicating that
the PI3K-AKT pathway is downregulated in the BM niche(41)
(Fig. 2). In the absence of growth factor stimulation, FoxO
proteins are retained in an active state in the nucleus and
induce their transcriptional targets. We and others have shown
that FoxOs are essential for the maintenance of quiescence and
self-renewal capacity in HSCs in vivo.(42–44) Consistent with
the suppression of PI3K-AKT signaling observed in HSCs,
mTORC1 is downregulated in these cells. Indeed, studies of
Tsc1-deficient mice have demonstrated that mTORC1 suppres-
sion is essential for HSC quiescence.(45,46) In the absence of
Tsc1, phospho-S6 accumulates in HSCs, inducing their
entrance into the cell cycle. Tsc1-deficient HSCs exhibit
increased mitochondrial mass and mitochondrial DNA per
HSC. The transcription of many mitochondrial genes is ele-
vated, indicating that mTORC1 activation triggers mitochon-
drial biogenesis. In addition, Tsc1-deficient HSCs show
increased concentrations of reactive oxygen species (ROS).
Interestingly, although Tsc1 deletion induces a transient
increase in HSC numbers in these mutant mice, these cells
eventually become exhausted. Suppression of ROS level by
treatment with the antioxidant molecule N-acetylcysteine
(NAC) can prevent the phenotypic defects of Tsc1-deficient
HSCs. Thus, suppression of mTORC1 contributes to HSC
maintenance by repressing mitochondrial biogenesis.
HSC functions decline with age in mammals in a manner
reportedly due to increased mTORC1 activity.(47) In HSCs
from aged mice, the phosphorylated forms of S6K, S6 and
AKT are significantly elevated. Interestingly, aged mice treated
with the mTORC1 inhibitor rapamycin (also known as
sirolimus) have an extended lifespan and show restored HSC
self-renewal and normal hematopoiesis. A recent study has
revealed that rapamycin treatment combined with activation of
canonical Wnt–b-catenin signaling maintains murine and
human HSCs ex vivo and increases the number of long-term
HSCs in vivo.(48) Thus, a microenvironment in which
mTORC1 is suppressed is critical for the maintenance of HSC
homeostasis.
The Abnormal Activation of mTORC1 or mTORC2 Associated
with Pten Deficiency Impairs HSC Functions. Phosphatase and
Tensin Homolog (PTEN) is a negative regulator of PI3K-AKT
signaling. Pten deficiency in mice disrupts HSC quiescence,
leading to HSC depletion.(49,50) Pten-deficient HSCs show
increased phospho-AKT and elevated phospho-S6.(51) Because
rapamycin can reverse the defective phenotypes of Pten-defi-
cient HSCs,(49) mTORC1 activation is thought to be responsi-
ble for HSC depletion. The mechanism of this depletion
appears to involve the upregulation of the tumor suppressors
p16 and p53 but is not mediated by ROS because NAC treat-
ment did not rescue the defective HSC phenotypes.(51)
mTORC2 is also responsible for the disrupted functions of
Pten-deficient HSCs.(52) The phosphorylation of AKT(S473),
which depends on mTORC2 activity, is increased in HSCs
upon Pten deletion. Furthermore, deficiency of Rictor, an
essential component of mTORC2, reduces AKT phosphoryla-
tion and restores the abilities of Pten-deficient HSCs to
undergo accelerated cell cycling and reconstitute the BM.(52)
Essential Role of mTOR Activation in Leukemogenesis
Abnormalities of mTOR signaling are observed in many
patients with leukemia, including those suffering from AML, T
cell acute lymphoblastic leukemia (T-ALL), Philadelphia chro-
mosome positive B precursor acute lymphoblastic leukemia
(Ph+B-ALL), B cell chronic lymphocytic leukemia (B-CLL),
CML, and high-risk myelodysplastic syndromes (MDS).(53,54)
Alterations in PTEN, PI3K or AKT are particularly frequent in
T-ALL patients.(55) In addition, although genetic aberrations in
the PI3K-AKT-mTOR pathway are not found in many AML
patients, mTORC1 is often activated. Therefore, it has been
suggested that mTORC1 may be activated by a pathway inde-














Fig. 2. mTOR signaling in the maintenance of HSC functions. In qui-
escent HSCs within the BM niche, PI3K-AKT signaling is suppressed.
mTORC1 is inactivated and FoxO transcription factors are activated.
The transcription of antioxidant genes such as superoxide dismutase
(SOD) and catalase can proceed. Failure of mTORC1 suppression or
FoxO inactivation results in an increase in ROS levels, leading to HSC
dysfunction. It remains unclear how mTORC1 and FoxOs are regulated
by signals emanating from the BM niche in vivo.
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Several groups have used genetically modified mouse models
to dissect the role of mTOR in leukemogenesis (Fig. 3). Pten
deficiency in murine hematopoietic cells promotes myelopro-
liferative disease followed by leukemia development.(49–51)
As mentioned above, since p53 is upregulated in HSCs by Pten
deficiency and loss of heterozygosity of p53 allele is found in
Pten deficiency-evoked leukemia,(51) secondary mutations of
tumor suppressors may be required for the leukemogenesis.
Because these phenotypes are inhibited by rapamycin, mTORC1
activation has been thought to induce leukemogenesis.(49)
Alternatively, since prolonged treatment of rapamycin report-
edly inhibits not only mTORC1, but also mTORC2, in some cell
lines,(56) rapamycin might suppress leukemogenesis via
mTORC2 inhibition. Consistent with this hypothesis, Raptor
deletion significantly prolongs the survival of Pten-
deficient mice and can ameliorate some of their neoplasia-
associated phenotypes.(57) Rictor deficiency can also reduce the
severity of myeloproliferative disease and leukemia
incidence.(52) Since AKT suppression mediated by mTORC2
inactivation may result in suppression of mTORC1 inactivation,
it has been suggested that mTORC2 plays a role in leukemogen-
esis evoked by Pten deficiency partly through its effects on
mTORC1.(52) Thus, both mTORC1 and mTORC2 play critical
roles in leukemogenesis.
Targeting mTOR Signaling for Leukemia Treatment
mTOR inhibitors. Rapamycin (Silolimus) and its derivative
“rapalogs”, including temsirolimus, everolimus and ridaforoli-
mus, are all allosteric inhibitors of mTORC1. Rapamycin binds
to FK506 binding protein 12 (FKBP12) to form a complex that
inactivates mTORC1.(8,9) Mice subjected to long-term treatment
with rapamycin also show mTORC2 inhibition, although the
mechanisms are unclear.(56,58) These effects on mTORC1 have
led to the investigation of rapalogs as therapies for tumors, and
everolimus and temsirolimus have been approved for the treat-
ment of renal cell carcinomas. With respect to leukemias, sev-
eral reports have indicated that rapalogs show only a mild effect
on AML cells. In a phase I ⁄ II clinical trial of everolimus, a pos-
sible benefit was observed in only one of five MDS patients and
in none of nine AML patients.(59) Similarly, a phase I dose esca-
lation study of rapamycin combined with the MEC (mitoxan-
trone, etoposide, cytarabine) chemotherapy regimen in patients
with relapsed, refractory, or untreated secondary AML showed
no evidence of synergy between MEC and rapamycin.(60) A
phase II clinical trial of everolimus in patients with previously
treated indolent hematologic malignancies resulted in a partial
response in four of 22 heavily pretreated CLL patients.(61) A
phase II study of ridaforolimus as treatment for 52 patients with
hematological malignancies showed that partial responses were
achieved in 10% of patients, while hematologic improvement
⁄ stable disease was observed in 40% of patients.(62)
The limited ability of rapalogs to exert tumor cell cytotoxicity
may be due to the presence of rapamycin-insensitive mTOR sub-
strates such as 4EBP1.(63,64) Adenosine triphosphate (ATP)-
competitive mTOR inhibitors are much better inactivators of
mTOR target gene phosphorylation. Indeed, the phosphoproteo-
mic analyses cited above have revealed that there are critical dif-
ferences in the spectrum of targets affected by rapamycin versus
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Fig. 3. Role of mTOR signaling in leukemogenesis induced by Pten
deletion. Pten deficiency in murine hematopoietic cells promotes mye-
loproliferative disease that is followed by leukemia development. Thus,
leukemogenesis is associated with PI3K-AKT activation in which PI3K
activates both mTORC1 and mTORC2. Deletion of either Raptor
(mTORC1 inactivation) or Rictor (mTORC2 inactivation) inhibits leuke-
mia development. Rapamycin, an allosteric mTORC1 inhibitor, sup-
presses the leukemogenesis, although it might also affect mTORC2.














Fig. 4. Distinct roles of mTORC1 in differentiated
versus undifferentiated leukemia cells in an AML
model in vivo. Murine AML stem cells in a BM niche
can self-renew via a pathway independent of
mTORC1, and so can survive when a treatment that
blocks mTORC1 is applied. These stem cells cannot
differentiate and propagate unless mTORC1. When
mTORC1 is reactivated in AML stem cells, the cells
can once again differentiate and propagate,
causing a recurrence of leukemia. Understanding of
the mechanisms by which AML stem cells self-renew
should suggest novel therapeutic approaches
that will successfully eradicate leukemia in a
combination with mTORC1 inhibition.
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agents affect mTORC2 as well as mTORC1. Consistent with
these observations, the ATP-competitive mTOR inhibitors
PP242(65) and OSI-027(66) have potent anti-leukemic effects.
Although a potential drawback to these agents is their inhibition
of multiple targets, which could lead to unwanted side-effects or
serious damage to normal tissues, these inhibitors are expected
to have powerful anti-leukemic effects.
mTORC1 inhibition by genetic modification in AML. Although
mTORC1 activation can clearly trigger leukemogenesis (as
described above), until recently it was not known if targeting
mTORC1 could affect the behavior of an established leukemia
in vivo. To address this question, we generated an MLL-AF9–
driven mouse model of AML and induced rapid deletion of the
Raptor gene once leukemia was established.(67) In AML-bearing
mice, Raptor deficiency significantly suppressed leukemia pro-
gression by inducing the apoptosis of differentiated, but not
undifferentiated, leukemia cells. However, a subset of AML
cells that had an undifferentiated phenotype and was highly
enriched for leukemia-initiating cells was able to survive long-
term in vivo without mTORC1 activity (Fig. 4). The re-intro-
duction of the Raptor gene into these Raptor-deficient AML
cells induced them to propagate and differentiate, indicating that
although the tumor-propagating properties of AML stem cells
are dependent on mTORC1, their self-renewal capacity is not.
The observation that the survival and cell cycling of AML
stem cells in vivo were not altered by mTORC1 inactivation
was puzzling because phosphorylation of mTORC1 targets,
including a rapamycin insensitive substrate, 4EBP1, was
dramatically suppressed in these cells. Although 4EBP1 phos-
phorylation reportedly induces cap-dependent protein transla-
tion, which controls the growth of individual cells, deletion of
Raptor had no effect on the cell size of AML stem cells.
Since AKT phosphorylation was attenuated in Raptor deficient
AML cells, it is not the case that AKT activation by a feed-
back loop of mTORC1 inhibition supports survival of AML
stem cells. Microenvironmental factors possibly support
mTORC1-independent survival of AML stem cells. In this
case, combined therapies with inhibition of both such microen-
vironmental factors and mTORC1 activity may lead to novel
therapeutic approaches that will successfully eradicate AML
stem cells. Further dissection of the mechanisms and regula-
tion underlying the mTORC1-independent survival of AML
cells in the BM niche is needed.
Perspectives
In this review, we have focused on recent advances in under-
standing the roles of mTOR signaling in HSC and LSC biol-
ogy. The findings we have presented collectively suggest that
the mechanisms controlling mTOR activity are critical for the
physiological and pathological regulation of both normal and
malignant hematopoiesis. Although the roles of mTOR signal-
ing in LSCs are very complicated, LSC behavior may be
controlled by similar machinery governing the behavior of
normal HSCs and ⁄or hematopoietic progenitors. Therefore, a
detailed comparison of mTOR signaling pathways and targets
in HSCs and LSCs cells may provide valuable insights useful
for overcoming the current limitations of leukemia therapy.
Increased understanding of the mechanisms by which LSCs
self-renew may point the way to novel therapeutic approaches
that can successfully eradicate leukemia.
Acknowledgments
This work was partly supported by a Grant-in-Aid for Scientific
Research on Innovative Areas and the Project for Development of
Innovative Research on Cancer Therapeutics (P-DIRECT) from the
Ministry of Education, Culture, Sports, Science and Technology, Japan.
Disclosure Statement
The authors have no conflict of interest.
References
1 Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierar-
chy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:
730–7.
2 Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and
cancer stem cells. Nature 2001; 414: 105–11.
3 Naka K, Hoshii T, Tadokoro Y, Hirao A. Molecular pathology of tumor-
initiating cells: lessons from Philadelphia chromosome-positive leukemia.
Pathol Int 2011; 61: 501–8.
4 Goardon N, Marchi E, Atzberger A et al. Coexistence of LMPP-like and
GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011;
19: 138–52.
5 Krivtsov AV, Twomey D, Feng Z et al. Transformation from committed
progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442:
818–22.
6 Somervaille TC, Matheny CJ, Spencer GJ et al. Hierarchical maintenance
of MLL myeloid leukemia stem cells employs a transcriptional program
shared with embryonic rather than adult stem cells. Cell Stem Cell 2009; 4:
129–40.
7 Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL.
Similar MLL-associated leukemias arising from self-renewing stem cells and
short-lived myeloid progenitors. Genes Dev 2003; 17: 3029–35.
8 Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational
control. Nat Rev Mol Cell Biol 2009; 10: 307–18.
9 Laplante M, Sabatini DM. mTOR signaling in growth control and disease.
Cell 2012; 149: 274–93.
10 Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic
stem cells in the hypoxic niche. Cell Stem Cell 2011; 9: 298–310.
11 Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2
GAP activity and regulates mTOR signaling. Genes Dev 2003; 17: 1829–34.
12 Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis
complex gene products, Tuberin and Hamartin, control mTOR signaling by
acting as a GTPase-activating protein complex toward Rheb. Curr Biol
2003; 13: 1259–68.
13 Thedieck K, Polak P, Kim ML et al. PRAS40 and PRR5-like protein are
new mTOR interactors that regulate apoptosis. PLoS ONE 2007; 2: e1217.
14 Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signal-
ling to mTOR mediated by the Akt ⁄ PKB substrate PRAS40. Nat Cell Biol
2007; 9: 316–23.
15 Sancak Y, Thoreen CC, Peterson TR et al. PRAS40 is an insulin-regulated
inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25: 903–15.
16 Wang L, Harris TE, Roth RA, Lawrence JC Jr. PRAS40 regulates mTORC1
kinase activity by functioning as a direct inhibitor of substrate binding.
J Biol Chem 2007; 282: 20036–44.
17 Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphoryla-
tion and functional inactivation of TSC2 by Erk implications for tuberous
sclerosis and cancer pathogenesis. Cell 2005; 121: 179–93.
18 Inoki K, Ouyang H, Zhu T et al. TSC2 integrates Wnt and energy signals
via a coordinated phosphorylation by AMPK and GSK3 to regulate cell
growth. Cell 2006; 126: 955–68.
19 Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to
control cell growth and survival. Cell 2003; 115: 577–90.
20 Gwinn DM, Shackelford DB, Egan DF et al. AMPK phosphorylation of
raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214–26.
21 Brugarolas J, Lei K, Hurley RL et al. Regulation of mTOR function in
response to hypoxia by REDD1 and the TSC1 ⁄ TSC2 tumor suppressor
complex. Genes Dev 2004; 18: 2893–904.
22 DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates
TSC1 ⁄ 2-mTOR signaling and tumor suppression through REDD1-mediated
14-3-3 shuttling. Genes Dev 2008; 22: 239–51.
23 Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of
TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008; 10:
935–45.
24 Sancak Y, Peterson TR, Shaul YD et al. The Rag GTPases bind raptor and
mediate amino acid signaling to mTORC1. Science 2008; 320: 1496–501.
Hirao and Hoshii Cancer Sci | August 2013 | vol. 104 | no. 8 | 981
© 2013 Japanese Cancer Association
25 Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM.
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is
necessary for its activation by amino acids. Cell 2010; 141: 290–303.
26 Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis.
Curr Biol 2009; 19: R1046–52.
27 Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of
lipid homeostasis. Cold Spring Harb Symp Quant Biol 2002; 67: 491–8.
28 Peterson TR, Sengupta SS, Harris TE et al. mTOR complex 1 regulates lipin
1 localization to control the SREBP pathway. Cell 2011; 146: 408–20.
29 Ramanathan A, Schreiber SL. Direct control of mitochondrial function by
mTOR. Proc Natl Acad Sci USA 2009; 106: 22229–32.
30 Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserv-
er P. mTOR controls mitochondrial oxidative function through a YY1-PGC-
1alpha transcriptional complex. Nature 2007; 450: 736–40.
31 Rabinowitz JD, White E. Autophagy and metabolism. Science 2010; 330:
1344–8.
32 Hosokawa N, Hara T, Kaizuka T et al. Nutrient-dependent mTORC1 associ-
ation with the ULK1-Atg13-FIP200 complex required for autophagy.
Mol Biol Cell 2009; 20: 1981–91.
33 Hsu PP, Kang SA, Rameseder J et al. The mTOR-regulated phosphoprote-
ome reveals a mechanism of mTORC1-mediated inhibition of growth factor
signaling. Science 2011; 332: 1317–22.
34 Yu Y, Yoon SO, Poulogiannis G et al. Phosphoproteomic analysis identifies
Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.
Science 2011; 332: 1322–6.
35 Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by
association with the ribosome. Cell 2011; 144: 757–68.
36 Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls
the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:
1122–8.
37 Sarbassov DD, Ali SM, Kim DH et al. Rictor, a novel binding partner of
mTOR, defines a rapamycin-insensitive and raptor-independent pathway that
regulates the cytoskeleton. Curr Biol 2004; 14: 1296–302.
38 Guertin DA, Stevens DM, Thoreen CC et al. Ablation in mice of the
mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is
required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell
2006; 11: 859–71.
39 Jacinto E, Facchinetti V, Liu D et al. SIN1 ⁄ MIP1 maintains rictor-mTOR
complex integrity and regulates Akt phosphorylation and substrate specific-
ity. Cell 2006; 127: 125–37.
40 Naka K, Hirao A. Maintenance of genomic integrity in hematopoietic stem
cells. Int J Hematol 2011; 93: 434–9.
41 Yamazaki S, Iwama A, Takayanagi S et al. Cytokine signals modulated via
lipid rafts mimic niche signals and induce hibernation in hematopoietic stem
cells. EMBO J 2006; 25: 3515–23.
42 Miyamoto K, Araki KY, Naka K et al. Foxo3a is essential for maintenance
of the hematopoietic stem cell pool. Cell Stem Cell 2007; 1: 101–12.
43 Tothova Z, Kollipara R, Huntly BJ et al. FoxOs are critical mediators of
hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007;
128: 325–39.
44 Yalcin S, Zhang X, Luciano JP et al. Foxo3 is essential for the regulation of
ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of
hematopoietic stem cells. J Biol Chem 2008; 283: 25692–705.
45 Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Zheng P. TSC-mTOR main-
tains quiescence and function of hematopoietic stem cells by repressing
mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008; 205:
2397–408.
46 Gan B, Sahin E, Jiang S et al. TORC1-dependent and -independent regula-
tion of stem cell renewal, differentiation, and mobilization. Proc Natl Acad
Sci USA 2008; 105: 19384–9.
47 Chen C, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of
aging hematopoietic stem cells. Sci Signal 2009; 2: ra75.
48 Huang J, Nguyen-McCarty M, Hexner EO, Danet-Desnoyers G, Klein PS.
Maintenance of hematopoietic stem cells through regulation of Wnt and
mTOR pathways. Nat Med 2012; 18: 1778–85.
49 Yilmaz OH, Valdez R, Theisen BK et al. Pten dependence distinguishes hae-
matopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441:
475–82.
50 Zhang J, Grindley JC, Yin T et al. PTEN maintains haematopoietic stem
cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441:
518–22.
51 Lee JY, Nakada D, Yilmaz OH et al. mTOR activation induces tumor sup-
pressors that inhibit leukemogenesis and deplete hematopoietic stem cells
after Pten deletion. Cell Stem Cell 2010; 7: 593–605.
52 Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL, Morrison CG. Tempo-
ral Changes in PTEN and mTORC2 regulation of hematopoietic stem cell
self-renewal and leukemia suppression. Cell Stem Cell 2012; 11: 415–28.
53 Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin
pathway in hematologic malignancies. Curr Opin Hematol 2008; 15: 88–94.
54 Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibi-
tors and their potential role in therapy in leukaemia and other haematological
malignancies. Br J Haematol 2009; 145: 569–80.
55 Gutierrez A, Sanda T, Grebliunaite R et al. High frequency of PTEN, PI3K,
and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009;
114: 647–50.
56 Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment
inhibits mTORC2 assembly and Akt ⁄ PKB. Mol Cell 2006; 22: 159–68.
57 Kalaitzidis D, Sykes SM, Wang Z et al. mTOR complex 1 Plays critical
roles in hematopoiesis and pten-loss-evoked leukemogenesis. Cell Stem Cell
2012; 11: 429–39.
58 Phung TL, Ziv K, Dabydeen D et al. Pathological angiogenesis is induced
by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006;
10: 159–70.
59 Yee KW, Zeng Z, Konopleva M et al. Phase I ⁄ II study of the mammalian
target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed
or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165–73.
60 Perl AE, Kasner MT, Tsai DE et al. A phase I study of the mammalian tar-
get of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and
refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15: 6732–9.
61 Zent CS, LaPlant BR, Johnston PB et al. The treatment of recurrent ⁄ refrac-
tory chronic lymphocytic leukemia ⁄ small lymphocytic lymphoma (CLL)
with everolimus results in clinical responses and mobilization of CLL cells
into the circulation. Cancer 2010; 116: 2201–7.
62 Rizzieri DA, Feldman E, Dipersio JF et al. A phase 2 clinical trial of defo-
rolimus (AP23573, MK-8669), a novel mammalian target of rapamycin
inhibitor, in patients with relapsed or refractory hematologic malignancies.
Clin Cancer Res 2008; 14: 2756–62.
63 Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG. Distinct signal-
ing events downstream of mTOR cooperate to mediate the effects of amino
acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol
2005; 25: 2558–72.
64 Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially
inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA
translation. Proc Natl Acad Sci USA 2008; 105: 17414–9.
65 Janes MR, Limon JJ, So L et al. Effective and selective targeting of leuke-
mia cells using a TORC1 ⁄ 2 kinase inhibitor. Nat Med 2010; 16: 205–13.
66 Carayol N, Vakana E, Sassano A et al. Critical roles for mTORC2- and
rapamycin-insensitive mTORC1-complexes in growth and survival of
BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010; 107:
12469–74.
67 Hoshii T, Tadokoro Y, Naka K et al. mTORC1 is essential for leukemia
propagation but not stem cell self-renewal. J Clin Invest 2012; 122:
2114–29.
982 doi: 10.1111/cas.12189
© 2013 Japanese Cancer Association
